Literature DB >> 34603985

Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.

Yannick Silva1, Jean-Marc Riedinger1, Marie-Lorraine Chrétien2, Denis Caillot2, Jill Corre3,4, Kévin Guillen5, Alexandre Cochet1,6, Claire Tabouret-Viaud1, Romaric Loffroy5.   

Abstract

BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (18F-FDG PET/CT) is a useful tool for baseline staging in newly diagnosed multiple myeloma (MM) but also for prognostic stratification. This monocentric retrospective study aimed at examining the relation between baseline tumour metabolism assessed by 18F-FDG PET/CT and linear predictor (LP) score, a new cytogenetic stratification score.
METHODS: From March 2012 to March 2019, 57 patients with newly diagnosed MM addressed to our institution for baseline 18F-FDG PET/CT were included. LP score was determined on systematic iliac crest bone marrow samples. Obtained on CD138-sorted bone marrow plasma cells, this recent composite cytogenetic stratification is a 6-marker based weighted score using fluorescence in situ hybridization (FISH) ± single nucleotide polymorphism (SNP) arrays. We compared quantitative metabolic parameters and LP score using a Kruskal-Wallis test and visual suspicion of diffuse bone marrow involvement (DBI; based on hepatic background as threshold of positivity) and cytogenetic data using a Chi-squared test.
RESULTS: The distribution of total metabolic tumour volume (TMTV) and total lesion glycolysis (TLG) values among the three LP score categories was almost stochastic, with no significant association (P=0.70). Additionally, no significant association between TMTV/TLG and any of the six cytogenetic abnormalities included in LP score calculation. A significant association was found between visual high suspicion of DBI and LP score (P=0.036), and between this visual parameter and the presence of 1q gain (P=0.049).
CONCLUSIONS: There is no significant association between quantitative metabolic parameters assessed with 18F-FDG PET/CT and LP score in patients with newly diagnosed MM, suggesting a potential complementarity of these biomarkers for prognostic stratification. A significant association was found between high visual suspicion of DBI and LP score. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  18F-fluorodeoxyglucose positron emission tomography integrated with computed tomography (18F-FDG PET/CT); Multiple myeloma (MM); cytogenetic stratification; linear predictor score (LP score); metabolic volume

Year:  2021        PMID: 34603985      PMCID: PMC8408794          DOI: 10.21037/qims-21-85

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  40 in total

1.  Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).

Authors:  Cristina Nanni; Annibale Versari; Stephane Chauvie; Elisa Bertone; Andrea Bianchi; Marco Rensi; Marilena Bellò; Andrea Gallamini; Francesca Patriarca; Francesca Gay; Barbara Gamberi; Pietro Ghedini; Michele Cavo; Stefano Fanti; Elena Zamagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-21       Impact factor: 9.236

Review 2.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Authors:  Michele Cavo; Evangelos Terpos; Cristina Nanni; Philippe Moreau; Suzanne Lentzsch; Sonja Zweegman; Jens Hillengass; Monika Engelhardt; Saad Z Usmani; David H Vesole; Jesus San-Miguel; Shaji K Kumar; Paul G Richardson; Joseph R Mikhael; Fernando Leal da Costa; Meletios-Athanassios Dimopoulos; Chiara Zingaretti; Niels Abildgaard; Hartmut Goldschmidt; Robert Z Orlowski; Wee Joo Chng; Hermann Einsele; Sagar Lonial; Bart Barlogie; Kenneth C Anderson; S Vincent Rajkumar; Brian G M Durie; Elena Zamagni
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

3.  Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

Authors:  Elena Zamagni; Francesca Patriarca; Cristina Nanni; Beatrice Zannetti; Emanuela Englaro; Annalisa Pezzi; Paola Tacchetti; Silvia Buttignol; Giulia Perrone; Annamaria Brioli; Lucia Pantani; Carolina Terragna; Francesca Carobolante; Michele Baccarani; Renato Fanin; Stefano Fanti; Michele Cavo
Journal:  Blood       Date:  2011-09-06       Impact factor: 22.113

4.  Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.

Authors:  Michael Mulligan; Alin Chirindel; Michael Karchevsky
Journal:  Cancer Invest       Date:  2011-06       Impact factor: 2.176

5.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Authors:  Salim Kanoun; Cédric Rossi; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Alexandre Cochet; Olivier Humbert; Michel Toubeau; Emmanuelle Ferrant; François Brunotte; René-Olivier Casasnovas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-09       Impact factor: 9.236

6.  Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

Authors:  James E McDonald; Marcus M Kessler; Michael W Gardner; Amy F Buros; James A Ntambi; Sarah Waheed; Frits van Rhee; Maurizio Zangari; Christoph J Heuck; Nathan Petty; Carolina Schinke; Sharmilan Thanendrarajan; Alan Mitchell; Antje Hoering; Bart Barlogie; Gareth J Morgan; Faith E Davies
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

7.  Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease.

Authors:  P Spinnato; A Bazzocchi; A Brioli; C Nanni; E Zamagni; U Albisinni; M Cavo; S Fanti; G Battista; E Salizzoni
Journal:  Eur J Radiol       Date:  2012-08-24       Impact factor: 3.528

8.  Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation.

Authors:  Antje Stolzenburg; Katharina Lückerath; Samuel Samnick; Martin Speer; Katharina Kneer; Jan-Stefan Schmid; Götz Ulrich Grigoleit; Susanne Hofmann; Ambros J Beer; Donald Bunjes; Stefan Knop; Andreas K Buck; Hermann Einsele; Constantin Lapa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-02       Impact factor: 9.236

9.  Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Authors:  Salim Kanoun; Ilan Tal; Alina Berriolo-Riedinger; Cédric Rossi; Jean-Marc Riedinger; Jean-Marc Vrigneaud; Louis Legrand; Olivier Humbert; Olivier Casasnovas; François Brunotte; Alexandre Cochet
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

10.  Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Authors:  Charlotte Pawlyn; Lorenzo Melchor; Alex Murison; Christopher P Wardell; Annamaria Brioli; Eileen M Boyle; Martin F Kaiser; Brian A Walker; Dil B Begum; Nasrin B Dahir; Paula Proszek; Walter M Gregory; Mark T Drayson; Graham H Jackson; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2014-11-26       Impact factor: 25.476

View more
  2 in total

1.  Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module.

Authors:  Jin Li; Yixin Liu; Wenlei Dong; Yang Zhou; Jingquan Wu; Kuan Luan; Lishuang Qi
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  Case report: Thoracic and lumbar plasma cell myeloma mimicking hemangiomas on MRI and 18F-FDG PET/CT.

Authors:  Xianwen Hu; Wei Xiong; Shun Li; Xue Li; Jiong Cai; Pan Wang; Dandan Li
Journal:  Front Med (Lausanne)       Date:  2022-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.